Patents Assigned to Sigma-Tau Industrie Farmaceutiche
  • COMPOSITION USEFUL FOR THE PREVENTION OR REDUCTION OF THE PROGRESSION OF PROSTATE CANCER
    Publication number: 20110262417
    Abstract: It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer.
    Type: Application
    Filed: July 24, 2009
    Publication date: October 27, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Franco Gaetani, Ashraf Virmani
  • Aminoderivative of biotin and their conjugates with macrocyclic chelating agents
    Patent number: 8044081
    Abstract: Formula (I) compounds are described where the groups are as defined here below, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: October 25, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Giovanni Paganelli, Marco Chinol, Mauro Ginanneschi
  • Use of thymosin alpha 1 for the treatment of immunological diseases
    Patent number: 8022036
    Abstract: It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: September 20, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Luigina Romani, Francesco Bistoni, Enrico Garaci
  • Amino derivatives of beta-homoandrostanes and beta-heteroandrostanes
    Patent number: 8022203
    Abstract: New aminoalkoxyimino derivatives at position 3 of substituted B-homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: September 20, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Alberto Cerri, Barbara Moro, Maco Torri, Giulio Carzana, Giuseppe Bianchi, Mara Ferrandi, Patrizia Ferrari, Maria Pia Zappavigna, Leonardo Banfi, Giuseppe Giacalone
  • COMPOUND USEFUL FOR TREATING CELLULITE
    Publication number: 20110217252
    Abstract: It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite.
    Type: Application
    Filed: November 5, 2009
    Publication date: September 8, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventor: Aleardo Koverech
  • Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome
    Patent number: 8013016
    Abstract: The use of acetyl L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicament and/or dietetic product for the treatment of fibromyalgic syndrome.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: September 6, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Aleardo Koverech
  • Pharmaceutical compositions containing the long pentraxin PTX3
    Patent number: 8003109
    Abstract: Pharmaceutical compositions are described containing a long pentraxin PTX3, particularly human PTX3, for the therapy of infectious and inflammatory or tumor diseases; expression vectors containing cDNA coding for PTX3; recombinant host cells transfected with such vectors; a method for producing substantial amounts of PTX3 involving the culturing of such cells, and the use of said vectors in the gene therapy of tumors.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: August 23, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Barbara Bottazzi, Martino Introna, Alberto Mantovani, Annunciata Vecchi
  • Use of acetyl L-carnitine in combination with propionyl L-carnitine and Sildenafil for the treatment of erectile dysfunction
    Patent number: 8003652
    Abstract: The use of acetyl L-carnitine in combination with propionyl L-carnitine and sildenafil is described for the preparation of a medicament and/or dietetic product for the treatment of erectile dysfunction secondary to all those conditions in which there is distress or iatrogenic damage of the lesser pelvis within which the neurovascular bundles of the penis run.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: August 23, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite, S.p.A.
    Inventors: Aleardo Koverech, Giorgio Cavallini
  • Vector for efficient selection and/or maturation of an antibody and uses thereof
    Patent number: 8003383
    Abstract: It is described a vector suitable for efficient selection and/or maturation of a recombinant antibody characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: August 23, 2011
    Assignees: Sigma Tau Industrie Farmaceutiche Riunite S.pA., Tecnogen S.p.A.
    Inventors: Olga Minenkova, Emiliano Pavoni
  • Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
    Publication number: 20110189152
    Abstract: A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.
    Type: Application
    Filed: February 7, 2011
    Publication date: August 4, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Mohamed Ashraf Virmani, Aleardo Koverech
  • Solution containing carnitine for the storage and perfusion of organs awaiting transplantation
    Patent number: 7989158
    Abstract: A storage solution to maintain and perfuse organs awaiting transplantation comprising (a) an isotonic balanced solution comprising a physiologically acceptable amount of potassium, mono acidic phosphate, biacidic phosphate, chloride, sodium and bicarbonate ions; (b) 50-250 mM glucose; (c) 0.2-20 mM of an alkanoyl L-carnitine or a physiologically acceptable salt thereof; (d) 1-100 mM of L-carnitine or a physiologically acceptable salt thereof; (e) water is described. The storage solution can also include other components such as anti-oxidants and/or chelating agents.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: August 2, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Arduini Arduino, Aureli Tommaso
  • NOVEL DUAL TARGETING ANTITUMORAL CONJUGATES
    Publication number: 20110160147
    Abstract: The present invention relates to dual-targeting cytotoxic compounds of formula (I) and to their preparation. The described compounds are endowed with tumour specific action, incorporating three functional units: a tumour recognition moiety and a tumour selective enzymatic substrate sequence connected together by means of a spacer. These conjugates are designed to guarantee serum stability and, at the same time, the desired action inside the tumour cells as a result of enzymatic cleavability. [(L-D)nE]m-F-D-PI-SI-CT Formula (I).
    Type: Application
    Filed: September 2, 2009
    Publication date: June 30, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Alma Dal Pozzo, Emiliano Esposito, Minghong Ni, Sergio Penco, Claudio Pisano, Massimo Castorina, Loredana Vesci
  • CRYSTALLINE TEGLICAR
    Publication number: 20110136905
    Abstract: The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same.
    Type: Application
    Filed: July 31, 2008
    Publication date: June 9, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Walter Cabri, Mauro Marzi, Fabrizio Giorgi, Emanuela Tassoni
  • Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
    Patent number: 7956091
    Abstract: The use of propionyl L-carnitine in combination with acetyl L-carnitine, or one of their pharmaceutically acceptable salts, is disclosed for the preparation of a medicament, or of a nutritional supplement, for the prevention and/or treatment of the disorders of the male andropause caused by ageing or by chemical or surgical castration.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: June 7, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Aleardo Koverech, Giorgio Cavallini, Giulio Biagiotti
  • Medicament for the two-step perioperative therapy of solid tumours
    Patent number: 7935346
    Abstract: The present invention describes the use of an agent endowed with tumour tropism in combination with another agent with anticancer activity and with an affinity for the first agent for the preparation of a medicament useful for the two-step perioperative therapy of solid tumours. The advantages of the present invention consist in the greater, effective localisation of its anticancer activity, in the reduction of the number of administration steps and in the possibility of reducing the anticancer doses, with a resulting decrease in side effects, but without any loss of efficacy.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: May 3, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Giovanni Paganelli, Paolo Carminati, Umberto Veronesi
  • Use of L-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use
    Patent number: 7932291
    Abstract: The use of L-carnitine and its alkanoyl derivatives, optionally in the form of a pharmaceutically acceptable salt, as osmotic agents in the preparation of solutions for medical use, particularly for peritoneal dialysis, is described.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: April 26, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Arduino Arduini
  • USE OF L-CARNITINE FOR THE TREATMENT OF CARDIOVASCULAR DIESASES
    Publication number: 20110086917
    Abstract: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.
    Type: Application
    Filed: December 20, 2010
    Publication date: April 14, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventor: Aleardo Koverech
  • AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS
    Publication number: 20110053902
    Abstract: Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.
    Type: Application
    Filed: April 11, 2007
    Publication date: March 3, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Alberto Cerri, Marco Torri, Silvia Armaroli, Leonardo Banfi, Giuseppe Bianchi, Giulio Carzana, Patrizia Ferrari, Rosamaria Michaeletti, Simona Sputore, Maria Pia Zappavigna
  • Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
    Patent number: 7897641
    Abstract: A composition is disclosed which is suitable for the prevention and/or treatment of cell and tissue abnormalities of exogenous, toxic or metabolic origin and suitable for reducing the toxic effects of cyclosporin-A and other immunosuppressive agents, which may take the form of a food supplement or of an actual medicine, containing as its active ingredients in combination or separately packaged: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts, and (b) an amino acid selected from the group consisting of glycine, serine, alanine and arginine, or mixtures thereof.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: March 1, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Claudio Cavazza
  • Treatment of drug-resistant tumors
    Patent number: 7888368
    Abstract: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of drug-resistant tumors and/or for the administration to patients who show polymorphisms in the gene coding for DNA topoisomerase I.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: February 15, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Claudio Pisano, Loredana Vesci